Hologic and Lightwave Logic Stocks Hit 52-Week Highs on Strategic Milestones

Key Facts

1Hologic Inc stock reached a new 52-week high of $76.01.

2Hologic gained FDA approval for its Aptima HPV Assay for primary screening.

3Lightwave Logic stock hit a 52-week high of $8.79, reflecting a 762% surge over the past year.

4Lightwave Logic reported a 147% revenue increase in Q4 2025 and a development agreement with Tower Semiconductor.

Shares of Hologic Inc and Lightwave Logic Inc reached new 52-week highs following significant operational and financial developments. Hologic's stock climbed to $76.01, bolstered by the FDA's approval of its Aptima HPV Assay for primary screening. Meanwhile, Lightwave Logic hit a peak of $8.79, marking a remarkable 762% increase over the past year. The photonics company reported a 147% revenue surge in the fourth quarter of 2025 alongside a strategic partnership with Tower Semiconductor. While Hologic maintains stability during its leadership transition, Lightwave Logic's rapid growth has drawn investor attention despite potential valuation concerns. These milestones underscore the strong momentum within the medical technology and semiconductor sectors.